基石藥業(02616.HK):與EQRx合作項目提前通過美國許可
基石藥業-B(02616.HK)公布就早前與EQRx Inc簽訂的舒格利單抗及CS1003(抗PD-1單抗)獨家許可協議,雙方達成的全球戰略合作協議已提前得到美國聯邦貿易委員會許可,通過美國1976 Hart-Scott-Rodino 反托拉斯改進法(HSR)的等待期。至此,該合作協議的全部條件已具備,交易正式生效。
根據協議條款,基石藥業將獲得1.5億美元的首付款,及最高可達11.5億美元的里程碑付款,以及額外的分級特許權使用費。
EQRx公司將獲得舒格利單抗和CS1003在除中國大陸、台灣地區、香港特區和澳門特區(大中華區)以外的全球市場的獨家商業化權利。基石藥業將保留C S1003在大中華區的開發和商業化權利,並將繼續探索其作為單藥和聯合療法的骨架產品的發展前景。(wl/t)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.